Irinotecan
Fallopian Tube Transitional Cell Carcinoma
M.D. Anderson Cancer CenterSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Fallopian Tube Transitional Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin National Cancer Institute (NCI) | Phase 3 | BBB |
(+)-VINCRISTINE M.D. Anderson Cancer Center | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
Cediranib National Cancer Institute (NCI) | Phase 3 | BB |
Olaparib National Cancer Institute (NCI) | Phase 3 | BB |
View all 22 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →